Undertreated chronic noncancer pain and growing misuse of opioids are two challenges presented by opioid therapy. A new Canadian guideline addresses these challenges with recommendations and tools for safe and responsible selection, prescription, titration and monitoring of opioids.¹

Chronic noncancer pain is a substantial public health problem in many societies,²–⁴ where it has immense negative impact both socially and economically. The most potent analgesics available, opioids have been shown to reduce pain from both nociceptive and neuropathic causes.⁵ Their efficacy in functional outcomes has been less obvious. Although some physicians are reluctant to prescribe opioids for chronic noncancer pain, Canadian prescribing trends of the past decade are disturbing. Canada’s recorded prescription-opioid consumption increased by about 50% between 2000 and 2004,⁶ a rate of increase greater than that of the United States during the same period. Canada is currently the world’s third-largest per capita consumer of opioid analgesics.⁷ The increase in opioid prescribing has been accompanied by increases in misuse, abuse, serious injuries and overdose-related deaths among people taking these drugs.⁸

Canadian medical regulators (i.e., colleges of physicians and surgeons) have recognized a growing need for guidance in opioid use for chronic noncancer pain. In November 2007, they formed the National Opioid Use Guideline Group to collaborate in developing the Canadian guideline for safe and effective use of opioids for chronic noncancer pain.¹ Their aim was to oversee the development and implementation of a guideline to assist physicians to manage patients with chronic noncancer pain by prescribing opioids in a safe and effective manner.

Scope

The Canadian guideline is intended to help physicians make appropriate decisions to start trials of opioid therapy for patients with chronic noncancer pain and to guide them in the monitoring of long-term opioid therapy, the detection of situations involving misuse, including addiction, and the appropriate response to such situations. The guideline was not designed to serve as a standard of care nor as a training manual. It addresses safe and effective prescribing of opioids for chronic noncancer pain (defined as pain that persists for more than six months)⁹ in male and female adolescents and adults, and is targeted to primary-care physicians, and medical and surgical specialists who manage patients with chronic noncancer pain. Pharmacists, nurses, and dentists may also find it useful. The scope of the guideline does not include use of opioids for acute pain or end-of-life pain, or treatment modalities and approaches for chronic noncancer pain other than opioids.

Development

Leadership

Three groups were instrumental in developing the Canadian guideline for safe and effective use of opioids for chronic noncancer pain. These groups were the National Opioid Use Guideline Group, a research group, and a national advisory panel. The role of the National Opioid Use Guideline Group was to oversee the development and implementation of the guideline; the group’s members were appointed by medical regulatory bodies. The research group comprised a research librarian, a physician-epidemiologist and four physician-researchers. This group was responsible for literature review,
quality appraisal, summary of the evidence, generation of the first draft of recommendations and revision of the recommendations using feedback from the national advisory panel.

The advisory panel consisted of 49 people invited to participate by the National Opioid Use Guideline Group. Selection of panel members was aimed at creating a well-balanced advisory body including multiple perspectives and varied experience. Selection was based on criteria that ensured cross-Canada representation from among the target audience (i.e., family physicians and other physicians who manage chronic noncancer pain), other health care providers (e.g., pharmacists, nurses, psychologists) and patients with chronic noncancer pain. The role of the advisory panel was to comment and reach consensus on recommendations for practice. Identities of panel members were blinded to the research group and other panel members until the panel’s last round of review.

Financial support for this work was provided by medical regulatory bodies; no funding was received from commercial organizations.

Literature review
For review of the literature, the research group relied on the meta-analysis reported in 2006 by Furlan and colleagues. Three new searches of the literature were also completed. The first targeted randomized controlled trials published since May 2006, with the goal of updating the Furlan meta-analysis. The second search targeted additional literature (i.e., studies of varying methodology) that addressed the treatment of chronic noncancer pain with opioids and managing the patient with problematic opioid use. The third search targeted additional literature (i.e., studies of varying methodology) that addressed long-term outcomes of opioid use.

In total, 6583 studies were identified; 184 (62 randomized controlled trials and 122 observational studies) met the criteria for inclusion and were used to develop recommendations. The methodologic quality of the randomized trials was assessed independently by two people using the Jadad instrument. The observational studies were not assessed for methodologic quality owing to lack of funding for experts in epidemiologic methods to perform the more complex and subjective reviews needed for observational studies.

During development of the Canadian guideline, additional searches of MEDLINE and www.guideline.gov were conducted for other guidelines on the same topic up to February 2009, and 15 relevant guidelines were selected for detailed evaluation.

| Table 1: Participation of members of the national advisory panel in modified Delphi process |
|-----------------|-----------------|-----------------|
| Round | Recommendations under review, no. | Panelists participating, % |
| 1 | 49 | 84 |
| 2 | 20 | 80 |
| 3 | 4 | 65 |
| 4 | 2 | 60 |

Practice recommendations
The research group provided methodologic and clinical expertise in the areas of chronic pain and addiction medicine. The group summarized evidence from the studies and drafted 49 initial recommendations that each included a discussion and related evidence. Final recommendations were produced using feedback from the national advisory panel through an iterative Modified Delphi process. Panelists received material via email and used an online survey tool to rate the relevance, feasibility and clarity of each recommendation, indicate their degree of agreement with each recommendation and provide open-ended comments.

Consensus was defined as support for a recommendation by 80% of panel respondents. Recommendations that did not receive this level of consensus were revised using feedback from the panel and rerated in the next round. With each round of review, panel members received a complete transcript of the written comments made by panelists in the previous round.

Although participation rates declined as the modified Delphi process progressed, the proportion of panel members involved remained high throughout (Table 1). Some drop-off occurring in the last two rounds may have been because of panel fatigue or related to the impact of the H1N1 influenza pandemic occurring in Canada at the time. Consensus on recommendations resulted after four rounds of electronic review and rating, culminating in a final meeting by telephone and web in which all panel members were invited to participate.

We adapted the system for grading levels of evidence developed by the Canadian Task Force on Preventive Health Care (Table 2) and used this adapted system to grade the recommendations of the Canadian guideline, which are presented in Table 3. Details of the method can be found in the guideline (http://nationalpaincentre.mcmaster.ca/opioid/).

Highlights
The 24 practice recommendations of the Canadian guideline, organized in five clusters, are listed in Table 3, along with a summary of how the guideline assists practitioners in implementing the recommendations. An example based on Recommendation 9: Optimal dose is presented in Appendices 1 and 2 (available at www.cmaj.ca/cgi/content/full/cmaj.100187/DC1).

The Canadian guideline addresses four clinical questions commonly considered by physicians when deciding to use opioids to treat chronic noncancer pain:
- What should I do before writing a prescription for opioids?
- How do I titrate the dosage of opioids?
- What should I do to ensure patient safety?
- When do I stop a patient’s opioid therapy?

The Canadian guideline includes numerous clinical tools (see http://nationalpaincentre.mcmaster.ca/opioid/).

What should I do before writing a prescription for opioids?
- Complete a thorough assessment to understand the nature of the pain and make an informed decision about whether opioids are a reasonable choice of treatment.
- Consider whether screening tools are needed to help identify whether the patient is at risk for opioid misuse or addiction.
• Manage the patient’s expectations by setting goals with the patient for functional improvement and pain reduction; these goals will be the outcomes used for measuring the opioid effectiveness.
• Ensure informed consent by reviewing potential benefits, risks, adverse effects and complications of opioid therapy with the patient.

How do I titrate the opioid dosage?
• Start with a low dosage, increase the dose gradually and monitor opioid effectiveness (i.e., an improvement in function or a reduction in pain intensity of at least 30%).
• Track the daily dose in morphine equivalence and monitor for the “watchful dose” (i.e., 200 mg morphine or equivalent per day). Therapy for most patients can be managed effectively below this amount. If you determine that the dosage required is beyond the watchful dose, reassess the pain to ensure opioids are the right therapy, reassess the risk for misuse and increase level of monitoring.
• Recognize that the optimal dose has been reached when three factors are in balance: the opioid is effective (i.e., the patient reports improved function or a reduction of at least 30% in pain intensity), effectiveness has reached a plateau (i.e., increasing the dosage yields negligible analgesic benefit), and no major adverse effects or complications are experienced.

What should I do to ensure patient safety?
• Use the goals for functional improvement and pain reduction that were set with the patient to monitor whether opioids are effective. Structured assessment tools may also be useful.
• Watch for aberrant drug-related behaviours that could signal opioid misuse. Tools available in the guideline can help with this.
• Assess factors that could impair the patient’s cognition and psychomotor ability, which could make driving unsafe.
• Use available consultation as needed (e.g., when pain is unresponsive, when opioid misuse or addiction is suspected), or in special populations (e.g., patients who are pregnant, elderly or adolescent, or who have comorbid psychiatric conditions).
• Collaborate with pharmacists to improve patient education and safety.

When do I stop a patient’s opioid therapy?
• Stop or switch opioids when adverse effects or risks are unacceptable or opioid effectiveness is insufficient.
• Discontinue opioids with a tapering dose protocol; avoid sedative-hypnotic drugs, especially benzodiazepines, during the taper.

Implementation
A national faculty was created to assist with implementation of the Canadian guideline. Thirty-five people from across the country were invited using criteria to ensure a mix of expertise and experience: educators (physician, interprofessional or patient education); those with a clinical focus or interest in topic; those connected to national or provincial knowledge-transfer infrastructure; or those perceived as a useful ambassador for the guideline.

The goals of the national faculty, as identified by participants, were to define outcomes of the implementation of the Canadian guideline and to develop plans to assist in implementation and evaluation. Activities initiated by the national faculty to ensure the Canadian guideline improves practice and patient outcomes will continue into the future, and coordination will be assumed by the Michael G. DeGroote National Pain Centre at McMaster University.

Updating
The Michael G. DeGroote National Pain Centre has accepted responsibility for stewardship of the Canadian guideline. This responsibility will include activities related to knowledge translation and updating the guideline by 2015.

<table>
<thead>
<tr>
<th>CTPHC grading system</th>
<th>Grade</th>
<th>Level of evidence</th>
<th>Adapted grading system for new Canadian guideline</th>
<th>Grade</th>
<th>Recommendation is supported by</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>I</td>
<td>Randomized controlled trials</td>
<td>A</td>
<td>Evidence from randomized controlled trial(s)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>II-1</td>
<td>Controlled trial(s) without randomization</td>
<td>B</td>
<td>Evidence from controlled trial(s) without randomization or</td>
<td></td>
</tr>
<tr>
<td></td>
<td>II-2</td>
<td>Cohort or case-control analytic studies, preferably from more than one centre or research group</td>
<td></td>
<td>Evidence from cohort or case-control analytic studies, preferably from more than one centre or research group or</td>
<td></td>
</tr>
<tr>
<td></td>
<td>II-3</td>
<td>Comparisons between times or places with or without the intervention (may include dramatic results from uncontrolled studies)</td>
<td></td>
<td>Evidence from comparisons between times or places with or without the intervention (may include dramatic results from uncontrolled studies)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>Opinions of respected authorities, based on clinical experience; descriptive studies or reports of expert committees</td>
<td>C</td>
<td>Consensus opinion of the national advisory panel</td>
<td></td>
</tr>
</tbody>
</table>
### Table 3: Recommendations of the Canadian guideline for safe and effective use of opioids for chronic noncancer pain (1 of 3)

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Grade(s)</th>
<th>Tools available in guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deciding to initiate opioid therapy</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 1 Comprehensive assessment | B, C | • A description of components of a comprehensive assessment  
• Guides to interviews on alcohol consumption and substance use  
• The CAGE questionnaire |
| 2 Screening for addiction risk | B | • An example of a screening tool (i.e., the Opioid Risk Tool) |
| 3 Urine screening for drugs | C | • Advice on patient education about urine screening for drugs, sample collection and tampering  
• Comparison of point-of-care versus laboratory urine testing  
• A list of the pros and cons of routine urine screening for drugs  
• A table of information about interpreting and acting on unexpected results  
• A table comparing immunoassay and chromatography, including detection times |
| 4 Opioid efficacy | A | • Summaries of findings from randomized controlled trials  
• Examples of conditions related to chronic noncancer pain for which opioids were shown to be effective in placebo-controlled trials and examples of conditions that have not been studied in controlled trials |
| 5 Risks, adverse effects and complications | B, C | • A summary of potential risks, benefits, adverse effects and complications of opioid therapy  
• Information about actions by physicians and education of patients and families aimed at reducing risks of overdose, diversion, addiction and withdrawal  
• A patient-information handout that can be customized to a physician’s practice  
• An example of a treatment agreement, with suggestions about when such an agreement might be useful |
| 6 Benzodiazepine tapering | B, C | • Protocol for tapering benzodiazepines  
• A table of benzodiazepine equivalence |
| **Conducting a trial of opioid therapy** | | |
| 7 Titration and driving | B, C | • Advice about conditions under which driving should be avoided during titration  
• A definition of "pharmacologically stable dose" |
| 8 Stepped selection of an opioid | C | • Guidance for selecting the most appropriate opioid while considering severity of pain and patient-safety issues |
### Table 3: Recommendations of the Canadian guideline for safe and effective use of opioids for chronic noncancer pain (2 of 3)

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Grade(s)</th>
<th>Tools available in guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Optimal dose</strong></td>
<td>C</td>
<td>• A definition of “optimal dose”</td>
</tr>
<tr>
<td>When conducting a trial of opioid therapy, start with a low dose, increase</td>
<td></td>
<td>• A table showing suggested initial dosage and titration</td>
</tr>
<tr>
<td>dosage gradually and monitor analgesic effectiveness until optimal dose is</td>
<td></td>
<td>• An example of how to assess change in pain intensity</td>
</tr>
<tr>
<td>attained.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Watchful dose</strong></td>
<td>A, C</td>
<td>• Advice about actions to take when the morphine-equivalent dosage approaches or exceeds 200 mg/d</td>
</tr>
<tr>
<td>Chronic noncancer pain can be managed effectively in most patients with</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dosages at or below 200 mg/d of morphine or equivalent (Grade A).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consideration of a higher dosage requires careful reassessment of the pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and of risk for misuse, and frequent monitoring with evidence of improved</td>
<td></td>
<td></td>
</tr>
<tr>
<td>patient outcomes (Grade C).</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Risk of misuse</strong></td>
<td>A, B, C</td>
<td>• A description of patients at higher risk for misuse</td>
</tr>
<tr>
<td>When initiating a trial of opioid therapy for patients at higher risk for</td>
<td></td>
<td>• A tool for detecting aberrant drug-related behaviours</td>
</tr>
<tr>
<td>misuse, prescribe only for well-defined somatic or neuropathic pain conditions</td>
<td></td>
<td>• Guidance on titration and monitoring in patients at higher risk for misuse</td>
</tr>
<tr>
<td>(Grade A), start with lower doses and titrate in small-dose increments (Grade B,)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and monitor closely for signs of aberrant drug-related behaviors (Grade C).</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Monitoring long-term opioid therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Monitoring</strong></td>
<td>C</td>
<td>• Information on elements of appropriate monitoring, including the value of physician–</td>
</tr>
<tr>
<td>When monitoring a patient on long-term therapy, ask about and observe for</td>
<td></td>
<td>pharmacist collaboration</td>
</tr>
<tr>
<td>opioid effectiveness, adverse effects or medical complications, and aberrant</td>
<td></td>
<td>• An example of a tool to monitor functional</td>
</tr>
<tr>
<td>drug-related behaviours.</td>
<td></td>
<td>improvement (i.e., the Brief Pain Inventory)</td>
</tr>
<tr>
<td><strong>Switching or discontinuing opioids</strong></td>
<td>B</td>
<td>• Examples of tools for monitoring patients for aberrant drug-related behaviours</td>
</tr>
<tr>
<td>For patients experiencing unacceptable adverse effects or insufficient</td>
<td></td>
<td>• An example of an opioid therapy record</td>
</tr>
<tr>
<td>opioid effectiveness from one particular opioid, try prescribing a different</td>
<td></td>
<td></td>
</tr>
<tr>
<td>opioid or discontinuing therapy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Driving and opioid therapy</strong></td>
<td>C</td>
<td>• Guidance on initial doses when switching to a different opioid</td>
</tr>
<tr>
<td>When assessing safety to drive in patients on long-term opioid therapy,</td>
<td></td>
<td>• Protocol for tapering opioids</td>
</tr>
<tr>
<td>consider factors that could impair cognition and psychomotor ability, such as</td>
<td></td>
<td>• A conversion table for opioid analgesics</td>
</tr>
<tr>
<td>a consistently severe pain rating, disordered sleep and concomitant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>medications that increase sedation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Revisiting steps of trial therapy</strong></td>
<td>C</td>
<td>• List of factors to assess that could impair cognition and psychomotor ability and thus</td>
</tr>
<tr>
<td>For patients receiving opioids for a prolonged period who may not have had</td>
<td></td>
<td>prompt a report of “unsafe to drive” to a regulatory body</td>
</tr>
<tr>
<td>an appropriate trial of therapy, take steps to ensure that long-term therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>is warranted and dose is optimal.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Collaborative care</strong></td>
<td>C</td>
<td>• A checklist to assist physicians with patients taking long-term opioid therapy who have</td>
</tr>
<tr>
<td>When referring patients for consultation, communicate and clarify roles and</td>
<td></td>
<td>not been through the steps of a therapy trial, to ensure nothing has been missed</td>
</tr>
<tr>
<td>expectations between primary-care physicians and consultants for continuity</td>
<td></td>
<td>• An outline of the process for revisiting diagnosis, screening, patient education,</td>
</tr>
<tr>
<td>of care and for effective and safe use of opioids.</td>
<td></td>
<td>selection and dosage of opioid and ensuring opioid effectiveness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Suggestions aimed at referring family physicians and consulting physicians on appropriate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>communication to ensure continuity of safe and effective care</td>
</tr>
</tbody>
</table>

Table 3 continues on next page.
Numerous other clinical practice guidelines address the management of chronic noncancer pain with opioids. A literature search showed that most other guidelines were either focused on a specific health problem (e.g., fibromyalgia, neuropathic pain, osteoarthritis, low-back pain) or were out of date.

Three current guidelines are similar to the Canadian guideline in scope, population, development, sponsorship,
recommendations and presentation. When work began on the Canadian guideline, only one of these three, the guideline of the American Society of Interventional Pain Physicians, had been published (originally in 200613 and updated in 2008).14 However, its target audience was interventional pain specialists. In 2009, when development of the Canadian guideline was well underway, the two other similar guidelines were published. The guideline of the American Pain Society and American Academy of Pain Medicine15 contains additional recommendations (not included in the Canadian guideline) on treatment of breakthrough pain, management of adverse effects, selection of short-acting versus long-acting preparations, special issues related to methadone, and awareness of state laws. The guideline of the Utah Department of Health16 is a compilation of recommendations from six other guidelines for the management of chronic noncancer pain with opioids. No major differences exist between the Utah and the Canadian guideline.

Limitations

The Canadian guideline is constrained by the paucity of supporting evidence in most of the topic areas in which recommendations for practice were considered necessary and relevant. This constraint necessitated a heavy reliance on the opinions and expertise of national advisory panels for developing recommendations. Our literature searches for observational studies used broad terms and might have missed relevant studies. Of the 183 studies used to support the recommendations, only 62 were randomized trials, and the remainder were observational studies. Given that the quality of the observational studies was not formally assessed, we used an adaptation of the grading system of the Canadian Task Force on Preventive Health Care. Another limitation of the published evidence was that functional outcomes studied were predominantly activities of daily living and quality of life. Other important outcomes, such as return to work, productivity and cognitive impairment, were rarely reported.

Potential long-term complications of opioid use (e.g., hypogonadism, opioid-induced hyperalgesia, sleep apnea, addiction) may occur even if the Canadian guideline recommendations are strictly followed.

Although an attempt was made to maintain a nationwide perspective, the national advisory panel pointed out numerous instances in which draft recommendations were dependent on access to resources not available in all parts of Canada (e.g., pain or addiction specialists, multidisciplinary pain management teams, prescription monitoring databases).

The Canadian guideline addresses only one modality for managing chronic noncancer pain — opioid therapy — and it does not discuss or provide guidance on other options. In spite of its narrow focus, the Canadian guideline is a lengthy and detailed document, and will need to be reformatted into feasible and practical tools for day-to-day use by busy practitioners. Screening tools are only valid when the patient’s reporting is accurate.

Finally, the National Opioid Use Guideline Group represents medical regulatory authorities, which could create concern that the Canadian guideline will be used as a standard of practice rather than for its intended purpose as advice to assist physicians.

Gaps in knowledge

Questions remain that cannot be answered confidently by the currently published randomized trials and that require appropriately designed studies of long-term opioid use for chronic noncancer pain. Gaps in knowledge remain in areas involving:

- Alternative routes of administration. More information is needed on efficacy and risk–benefit ratios of intramuscular, subcutaneous, transdermal, rectal and infusion routes of administration of opioids for chronic noncancer pain.
- Comparison of opioids with non-opioid drugs. Well-designed trials for equivalence and non-inferiority are needed to assess the relative effectiveness and risk–benefit ratios of opioids versus non-opioid drugs.
- Various clinical diagnoses. Most randomized trials on opioids for chronic noncancer pain concern musculoskeletal pain and neuropathic pain. Limited literature exists on treatment of fibromyalgia pain and chronic headache with opioids other than tramadol, and no useful literature exists on opioid treatment for chronic visceral pain.
- Long-term follow-up. Chronic noncancer pain is a long-term disorder, but the randomized controlled trials included in the current systematic review had fairly short follow-up periods. Well-designed long-term studies are needed to clarify the proportion of patients with chronic noncancer pain for whom opioids remain effective over months or years; the potential over extended time frames for opioid tolerance, hyperalgesia, loss of efficacy and complications such as hypogonadism, sexual dysfunction or central sleep apnea; and the probability of opioid misuse.
- Assessment of opioid misuse. Well-designed trials of sufficient duration are needed, with appropriate measures to identify prevalence and risks of opioid-related problems such as addiction.
- Populations with comorbidities. Trials are needed involving safe and appropriate management of chronic pain in patients with substantial comorbidity (e.g., pain in the elderly or in those with psychiatric comorbidity).
- Impact of research sponsorship. The majority of the randomized trials included in the systematic review were funded by the pharmaceutical industry. However, these studies did not include sufficient information to determine whether funding by the industry might have introduced publication bias. Whether small or unfavourable studies exist that were not submitted for publication is not known.
- The influence of genetic factors in opioid metabolism, analgesic response, incidence of adverse effects and predisposition to misuse and addiction.
This article has been peer reviewed.

Competing interests: Andrea Furlan is a contracted member of the drug advisory committee of the Workplace Safety and Insurance Board (WSIB) of Ontario. She has been contracted by the Common Drug Review of the Canadian Agency for Drugs and Technology in Health to review an opioid medication, has received honoraria to write an expert opinion paper for the WSIB on opioid use for chronic noncancer pain, and has received grants from the Canadian Institutes of Health Research and the Ontario Association of Fundraising Professionals Innovation Fund to conduct research on opioids.

The institution(s) of Rhoda Reardon and Clarence Wepppler received grants from the Federation of Medical Regulatory Authorities for this work. Rhoda Reardon is a full-time employee of the College of Physicians and Surgeons of Ontario, and Clarence Wepppler is a full-time employee of the College of Physicians and Surgeons of Alberta. Clarence Wepppler’s wife is an employee of Servier Canada, and his daughter is an employee of GlaxoSmithKline.

Contributors: Andrea Furlan led the research group responsible for the systematic review and evidence synthesis, and contributed extensively to the manuscript. Rhoda Reardon and Clarence Wepppler were co-chairs of the National Opioid Use Guideline Group (NOUGG), oversaw development of the guideline and coauthored the manuscript. All of the authors approved the final version of the manuscript submitted for publication.

Acknowledgements: Meldon Kahan and Angela Mailis-Gagnon led the development of the recommendations from initial draft, through revisions using feedback from the national advisory panel, to final copy. Emma Irvin designed and conducted the literature search, performed screening for relevance, and contributed methodological expertise on systematic reviews. Anita Srivastava and Luis Chaparro assisted with extraction of data and synthesis of evidence. Caroline Sutherland edited the guideline and the manuscript for this article. A full list of members of NOUGG is available at http://nationalpaincentre.mcmaster.ca/opioid/.

The National Opioid Use Guideline Group extends its sincere appreciation to members of the national advisory panel, whose contributions made the Canadian guideline possible, and the national faculty, for their continuing contribution in implementing the Canadian Guideline to practice.

Funding: NOUGG is grateful for support from the Federation of Medical Regulatory Authorities of Canada, the provincial and territorial medical regulatory authorities, and specifically acknowledges the significant contribution of funds and staff time from the College of Physicians and Surgeons of Ontario and the College of Physicians & Surgeons of Alberta. The authors acknowledge and appreciate funding from CIHR that enabled members of our national faculty to meet in person. No funding was received from any other source.

REFERENCES


Correspondence to: Clarence Wepppler, College of Physicians & Surgeons of Alberta, 2700, 10020–100 Street NW, Edmonton AB T5J 0N3; opioid-guideline@cpsa.ab.ca

Canadian guideline for safe and effective use of opioids for chronic non-cancer pain

http://nationalpaincentre.mcmaster.ca/opioid/